Professor Jayant Vaidya

Professional statement

Professor Jayant Vaidya is a prominent consultant oncoplastic breast surgeon and professor of surgery based in London, specialising in the diagnosis and treatment of diseases of the breast. With over 25 years of experience, Professor Vaidya is highly experienced in a wide range of treatments. His areas of expertise include breast cancer, lumpectomy, targeted intraoperative radiotherapy, mastectomy, breast preserving surgery and breast abscess, while his areas of surgical oncology expertise include sentinel node biopsy and intraoperative radiotherapy (TARGIT-IORT).  

Professor Vaidya received his first medical degree in 1988, graduating with an MBBS from the University of Bombay. He received his master of surgery from the same institution in 1991, before receiving a DNB in 1993. He then went on to become a fellow of both the Royal College of Surgeons of Glasgow and the Royal College of Surgeons of England, and in 2002 he received his PhD in surgical science from University College London.
 
Professor Vaidya currently practices privately at King Edward VII’s Hospital Sister Agnes and the London Clinic. In addition to his private practices, Professor Vaidya serves as an oncoplastic breast surgeon at several NHS hospitals across London. He is also a Professor of Surgery and Oncology at University College London.
 
He splits his time equally between research and clinical work, improving the understanding and treatment of breast cancer. He is extensively published, with over 200 scientific works over a wide range of medical fields, and has contributed to several books on breast cancer, including his own title 'Fast Facts: Breast Cancer´. 
 
He lectures and gives frequent talks on his specialty, both nationally and internationally, and is regularly invited to speak on the BBC as an expert in his field. He has also been featured in Time magazine, Reader's Digest, and Tomorrow's World, thanks to his pioneering of the concept of targeted intraoperative radiotherapy (TARGIT). This innovative take on radiotherapy enables women to receive radiotherapy at the time of surgery, instead of post-operative courses, enabling lower toxicity, and a safer, more focused treatment.